Rizact at a Glance
Rizatriptan is a selective 5-HT₁B/1D receptor agonist belonging to the triptan class of compounds developed for neurological research. This pharmaceutical-grade preparation from Cipla contains 10mg of active rizatriptan per tablet, enabling precise dosing protocols in laboratory investigations. As a second-generation triptan, rizatriptan demonstrates high oral bioavailability and rapid onset characteristics that make it valuable for studying serotonin receptor pathways and cranial vascular mechanisms. Research teams at Stroid UK Shop utilise this compound to investigate the molecular basis of migraine pathophysiology and evaluate therapeutic mechanisms in preclinical models.
Scientific Applications
Laboratory studies with rizatriptan focus on its selective binding affinity for 5-HT₁B and 5-HT₁D receptors, which are predominantly found in cranial blood vessels and trigeminal nerve terminals. Researchers examine how rizatriptan modulates vascular tone through receptor-mediated vasoconstriction and inhibits neuropeptide release from trigeminal neurons. The compound’s ability to cross the blood-brain barrier makes it particularly useful for investigating central nervous system mechanisms underlying headache disorders. Studies compare rizatriptan’s pharmacokinetic profile with other triptans, evaluating its superior bioavailability and shorter time to peak plasma concentration. Investigators studying rizatriptan research applications often examine its effects on CGRP (calcitonin gene-related peptide) release and substance P modulation in experimental models.
Product Specifications
| Parameter | Specification |
|---|---|
| Active Ingredient | Rizatriptan 10mg |
| Manufacturer | Cipla |
| Form | Oral tablets |
| CAS Number | 144034-80-0 |
| Molecular Formula | C15H19N5 |
| Molecular Weight | 269.35 g/mol |
| Storage | Room temperature, dry conditions |
Researchers conducting comparative studies often investigate rizatriptan alongside compounds available in our selective receptor modulators and neuropeptide research collections to understand broader neuropharmacological mechanisms.
Research Compliance
This rizatriptan preparation is manufactured by Cipla under pharmaceutical standards and supplied exclusively for in-vitro research and laboratory analysis. The compound is intended for qualified research institutions and licensed laboratories studying neurological mechanisms, receptor pharmacology, and migraine pathophysiology. Researchers must maintain appropriate documentation and storage conditions according to institutional guidelines. This product is not intended for human consumption, clinical use, or any application outside controlled laboratory environments.
